EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Relative efficacy of GLP ‐1 and GLP ‐1/ GIP receptor agonists in the prevention of alcohol‐use disorders using a target trial emulation approach

Alex E Henney iD, David R Riley, Megan Heague, Carl A Roberts, Theresa J Hydes, Matthew Anson, David M Hughes, Uazman Alam, Daniel J Cuthbertson

Diabetes, Obesity and Metabolism · 2026-01 · 28 (1) · 137-150

DOI: 10.1111/dom.70169 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 07.10.2025. Verfasst von Alex E Henney und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular & Metabolic Medicine, University of Liverpool, Liverpool, UK. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Alcoholism, Glucagon-Like Peptide-1 Receptor Agonists, Hypoglycemic Agents. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

There is growing evidence that the GLP‐1 system is implicated in alcohol and other substance use disorders, and that GLP‐1‐based therapies may have therapeutic relevance in alcohol use disorder (AUD). We aimed to determine the impact of GLP‐1 based therapies on incident AUDs in a real‐world setting in patients with T2D. Material and Methods We conducted emulation target trials based on a real‐world network of electronic health records (EHRs) from over 120 million patients in the United States of America. Four target trials were emulated among eligible patients with type 2 diabetes (T2D) who had no prior AUD diagnosis by comparing tirzepatide, semaglutide, liraglutide, and dulaglutide with DPP4 inhibitors (DPP4i). First‐ever diagnosis of AUD occurred within an 18‐month follow‐up period and was examined using Kaplan–Meier survival analyses. Four target trial cohorts were generated and compared with a reference arm of patients treated with DPP4i: cohort (1) treatment with tirzepatide; cohort (2) treatment with semaglutide; cohort (3) treatment with liraglutide; and cohort (4) treatment with dulaglutide. Cohorts underwent propensity score matching 1:1 for confounders. We examined rates of incident AUD (ICD‐10 code F10) and performed head‐to‐head analyses of the incretin‐based therapies. We also performed sensitivity analyses relating to whether treatment was adjunctive therapy with metformin and by treatment adherence.

Results

After propensity‐score matching, we identified four target trials of patients treated with tirzepatide ( n = 7165), semaglutide ( n = 20 198), liraglutide ( n = 6565), and dulaglutide ( n = 19 061); 1:1 with the reference (DPP4i) patients. Tirzepatide and semaglutide (but not liraglutide or dulaglutide) were associated with significant risk reduction of incident AUD compared to DPP4i (hazard ratio 0.47 [95% confidence interval 0.29, 0.75] and 0.68 [0.52, 0.89], respectively). Head‐to‐head comparison revealed tirzepatide had a significant risk reduction compared to liraglutide in incident AUD (0.47 [0.24, 0.92]).

Conclusion

In patients with T2D, tirzepatide and semaglutide treatment is associated with a lower incidence of AUD; robust randomised, controlled evidence for the use of these drugs for this novel indication is appropriate.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2AlcoholismGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsGlucagon-Like Peptide 1HumansGlucagon-Like PeptidesMaleLiraglutideFemaleMiddle AgedRecombinant Fusion ProteinsImmunoglobulin Fc FragmentsDipeptidyl-Peptidase IV InhibitorsTirzepatideAdultAgedTreatment OutcomeDrug Therapy, CombinationIncretinsReceptors, Gastrointestinal HormoneSemaglutide

Stichwörter der Autor:innen

GLP‐1 analoguecohort studyreal‐world evidencetype 2 diabetes

Substanzen

Glucagon-Like PeptidesLiraglutideRecombinant Fusion ProteinsGlucagon-Like Peptide-1 Receptor AgonistsImmunoglobulin Fc FragmentsHypoglycemic AgentsDipeptidyl-Peptidase IV InhibitorsGlucagon-Like Peptide 1TirzepatideIncretins

Autor:innen und Institutionen

  • Department of Cardiovascular & Metabolic Medicine, University of Liverpool, Liverpool, UK.
  • Metabolism & Nutrition Research Group, Liverpool University Hospitals NHS Foundation Trust, Merseyside, Liverpool, UK.
  • Liverpool Centre for Cardiovascular Sciences, University of Liverpool and Liverpool University Hospitals NHS Foundation Trust, Merseyside, Liverpool, UK.
  • Department of Psychology, Institute of Population Health, University of Liverpool, Merseyside, UK.
  • Deparment of Health Data Science, Institute of Population Health, University of Liverpool, Liverpool, UK.

ORCID-Profile: Alex E Henney

Zitieren

APA

Henney, A. E., Riley, D. R., Heague, M., Roberts, C. A., Hydes, T. J., Anson, M., Hughes, D. M., Alam, U., & Cuthbertson, D. J. (2026). Relative efficacy of GLP ‐1 and GLP ‐1/ GIP receptor agonists in the prevention of alcohol‐use disorders using a target trial emulation approach. Diabetes, Obesity and Metabolism, 28(1), 137-150. https://doi.org/10.1111/dom.70169

Vancouver

Henney AE, Riley DR, Heague M, Roberts CA, Hydes TJ, Anson M, et al. Relative efficacy of GLP ‐1 and GLP ‐1/ GIP receptor agonists in the prevention of alcohol‐use disorders using a target trial emulation approach. Diabetes, Obesity and Metabolism. 2026;28(1):137-150. doi:10.1111/dom.70169

BibTeX
@article{Henney2026,
  author = {Henney, Alex E and Riley, David R and Heague, Megan and Roberts, Carl A and Hydes, Theresa J and Anson, Matthew and Hughes, David M and Alam, Uazman and Cuthbertson, Daniel J},
  title = {Relative efficacy of GLP ‐1 and GLP ‐1/ GIP receptor agonists in the prevention of alcohol‐use disorders using a target trial emulation approach},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  volume = {28},
  number = {1},
  pages = {137--150},
  doi = {10.1111/dom.70169}
}
Kostenlos starten →